NEXINexImmune, Inc.

About NexImmune, Inc. (NEXI)

NexImmune, Inc. (NEXI) is a Biotechnology company headquartered in Gaithersburg, MD, United States whose shares trade over-the-counter on the Expert Market tier.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage.

NEXI key facts

Ticker symbol

NEXI

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Gaithersburg, MD, United States

Country of incorporation

US

Estimated market cap

$139.467 (as of Apr 11, 2025)

Shares outstanding

1,394,671

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Aug 21, 2024)

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with N